Supporting Information

Synthesis of Disubstituted Imidazo[4,5*b*]pyridin-2-ones

Jeffrey T. Kuethe, * Audrey Wong, and Ian W. Davies

Department of Process Research, Merck & Co., Inc., P.O. Box 2000, rahway, NJ 070765 <u>Jeffrey_Kuethe@merck.com</u>

Melting points are uncorrected. All solvents and reagents were used as received from commercial sources. Analytical samples were obtained by chromatography on silica gel using an ethyl acetate-hexane mixture as the eluent unless specified otherwise. Water content (KF) was determined by Karl Fisher titration on a Metrohm 737 KF coulometer.

Table of Contents

Compound 4	S2
General Procedures for Compounds 5-27	
Compounds 5-27	S3-S19
General Procedure for Compounds 28-38	S19-20
Compounds 28-38	S20-S28
NMR Spectra	S29-S37


Preparation of 2-Chloro-3-iodopyridine (4). In a 12 L flask was charged 900 mL of 5N HCl and 101.30 g (0.79 mol) of 3-amino-2-chloropyridine. The mixture was cooled to -5 °C and 81.6 g (1.18 mol) of sodium nitrite in 350 mL of water was added dropwise while maintaining the internal temperature below 5 °C. After 10 min, 288.50 g (1.74 mol) of KI in 350 mL of water was added dropwise at -5 °C while maintaining the internal temperature below 5 °C. After 10 min, 288.50 g (1.74 mol) of KI in 350 mL of water was added dropwise at -5 °C while maintaining the internal temperature below 10 °C over the course of the addition. The reaction mixture was warmed to rt and 1.50 L of EtOAc was added. The pH of the aqueous layer was adjusted to 11 by the addition of 650 mL of 6N NaOH, the layers were separated, and the organic layer was washed with 1.50 L of 0.3M Na₂S₂O₃. The EtOAc layer was concentrated and the residue re-dissolved in 500 mL of DMF. To the reddish/brown mixture was added dropwise 1.50 L of water and the slurry stirred for 30 min and filtered. The filter cake was washed with water (2 X 500 mL) and then dried under vacuum/N₂ sweep to provide 173.3 g (92%) of **4** where the spectroscopic properties were identical to that reported in the literature.¹

General Procedure for the Preparation of 3-amino-2-chloropyridines: To a slurry of 3.00 g (12.5 mmol) of 2-chloro-3-iodopyridine (4) in 31 mL of toluene was added sequentially 10.0 mg (0.376 mmol) of Pd(OAc)₂, 84.0 mg (0.376 mmol) of *rac*-BINAP, 1.37 g (62.5 mmol) of solid Cs₂CO₃, 11.9 mmol of the appropriate amine, and 75 mg (0.752 mmol) of triethylamine. The resulting slurry was degassed (2X) by vacuum/N₂ backfills. The mixture was heated to reflux and monitored by TLC (EtOAc/hexane) for the disappearance of starting materials. After 18 h the reaction mixture was cooled to rt and 30 mL of H₂O was added. The layers were separated and the toluene layer was

concentrated under reduced pressure. The residue could be used crude without further purification in the next reaction or purified by silica gel chromatography.


General Procedure for the Preparation of Unsymmetrically Substituted Diamines: To 3.00 mmol of the appropriate 3-amino-2-chloropyridine in 12 mL of toluene was added sequentially 41.0 mg (0.0450 mmol) of $Pd_2(dba)_3$, 84.0 mg (0.135 mmol) of *rac*-BINAP, 404 mg (4.20 mmol) of NaOtBu, and 3.60 mmol of the appropriate aniline. The reaction was degassed (2X) by vacuum/N₂ backfills. The mixture was heated to reflux and monitored by TLC (25% EtOAc/hexane) for the disappearance of starting materials. After 18 h the reaction mixture was cooled to rt and concentrated under reduced pressure. The residue could be used crude without further purification in the next reaction or purified by silica gel chromatography.

General Procedure for the Preparation of Imidazo[4,5-*b***]pyridin-2-ones:** To a solution of 1.0 mmol of the appropriate diamine in 6.7 mL of EtOAc or THF was added 2.5 mmol of triethylamine and 0.4 mmol of triphosgene. The resulting slurry was stirred at rt for 30 min and 7.0 mL of sat NaHCO₃ was added. The layers were separated and the organic layer was concentrated under reduced pressure.. The residue was purified by silica gel chromatography or recrystallized from an ethyl acetate/hexane mixture.




Preparation of 2-Chloro-N-phenylpyridin-3-amine (5). According to the general procedure for the preparation of 3-amino-2-chloropyridines, reaction of 7.00 g (29.23


mmol) of **4** with 2.63 g (28.25 mmol) of aniline gave 4.91 g (85%) of **5** which was used in the next step without further purification: ¹H NMR (CDCl₃, 400 MHz) δ 6.15 (br s, 1H), 7.07-7.18 (m, 4H), 7.37 (t, 2H, *J* = 7.7 Hz), 7.49 (d, 1H, *J* = 8.1 Hz), 7.87 (d, 1H, *J* = 4.5 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 121.2, 121.3, 123.9, 124.0, 129.7, 137.8, 139.4, 140.1, 151.8.



Preparation of N^2 -1,3-benzodioxol-5-yl- N^3 -phenylpyridin-2,3-diamine (6). According to the general procedure for the preparation of unsymmetrically substituted diamines, treatment of 2.20 g (10.8 mmol) of **5** with 1.77 g (12.9 mmol) of 3,4- (methylenedioxy)aniline afforded 2.63 g (80%) of **6** as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 5.22 (br s, 1H), 5.91 (s, 2H), 6.73 (m, 6H), 6.92 (t, 1H, J = 7.4 Hz), 7.26 (m, 3H), 7.39 (dd, 1H, J = 7.6 and 1.4 Hz), 8.06 (dd, 1H, J = 4.9 and 1.6 Hz); ¹³C NMR (CDCl₄, 100 MHz) δ 101.1, 103.0, 108.2, 112.9, 114.9, 115.9, 120.5, 124.8, 129.6, 131.8, 135.0, 143.0, 144.1, 144.8, 147.8, 152.3; Anal. Calcd. For C₁₃H₁₅N₃O₂: C, 70.81; H, 4.95; N, 13.76. Found: C, 70.55; H, 5.03; N, 13.88.




Preparation of 3-(1,3-benzodioxol-5-yl)-1-phenyl-1,3-dihydro-2*H*-imidazo[4,5*b*]pyridin-2-one (7). According to the general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatment of 1.50 g (4.91 mmol) of diamine **6** with 583 mg (1.97 mmol) of triphosgene gave 1.58 g (97%) of **7** as a colorless solid: mp 175-176 °C; ¹H NMR (CDCl₃, 400 MHz) δ 6.03 (s, 2H), 6.96 (d, 1H, *J* = 7.7 Hz), 7.05 (dd, 1H, *J* = 7.7 and 5.2 Hz), 7.20 (m, 2H), 7.35 (d, 1H, *J* = 7.7 Hz), 7.44 (m, 1H), 7.57 (m, 4H), 8.11 (d, 1H, *J* = 5.2 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 101.8, 107.9, 108.6, 115.0, 117.9, 120.3, 123.8, 125.7, 126.7, 128.1, 129.8, 133.9, 141.7, 143.7, 147.4, 148.2, 151.9; Anal. Calcd. For C₁₉H₁₃N₃O₃: C, 68.88; H, 3.95; N, 12.68. Found: C, 68.77; H, 3.86; N, 12.73.




2-Chloro-*N***-(2,2-dimethylpropyl)pyridin-3-amine (8).** According to the general procedure for the preparation of 3-amino-2-chloropyridines, reaction of 5.00 g (20.9 mmol) of **4** with 1.73 g (19.8 mmol) of neopentyl amine afforded 2.96 g (75%) of **8** which was used in the next step without further purification: ¹H NMR (CDCl₃, 400 MHz) δ 1.04 (s, 9H), 2.94 (d, 2H, *J* = 6.0 Hz), 4.42 (br s, 1H), 6.91 (dd, 1H, *J* = 8.0 and

1.6 Hz), 7.08 (dd, 1H, *J* = 8.0 and 4.4 Hz), 7.68 (dd, 1H, *J* = 4.8 and 1.6 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 27.6, 32.1, 50.6, 117.2, 123.4, 135.9, 137.0, 141.5.




 N^2 -(2,5-Difluorophenyl)- N^3 -(2,2-dimethylpropyl)pyridine-2,3-diamine (9). According to the general procedure for the preparation of unsymmetrically substituted diamines, treatment of 500 mg (2.52 mmol) of **8** with 320 mg (2.5 mmol) of 2,5-difluoroaniline gave 462 mg (63%) of **9** which was used in the next step without further purification. ¹H NMR (CDCl₃, 400 MHz) δ 1.04 (s, 9H), 2.86 (d, 2H, *J* = 6.4 Hz), 3.26 (br t, 1H, *J* = 6.0 Hz), 6.54 (m, 1H), 6.90 (dd, 1H, *J* = 8.0 and 4.8 Hz), 7.02 (m, 2H), 7.34 (br s, 1H), 7.78 (m, 1H), 7.84 (dd, 1H, *J* = 4.8 and 1.6 Hz).




3-(2,5-Difluorophenyl)-1-(2,2-dimethylpropyl)-1,3-dihydro-2H-imidazo[4,5-

b]pyridin-2-one (10). According to the general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatment of 730 mg (2.51 mmol) of diamine 9 with 430 mg (1.45 mmol) of triphosgene yielded 572 mg (72%) of 10 as a yellow crystalline solid:


mp 149-150 °C; ¹H NMR (CDCl₃, 400 MHz) δ 1.10 (s, 9 H), 3.74 (s, 2H), 7.09 (dd, 1H, J = 7.6 and 5.2 Hz), 7.16 (m, 1H), 7.29 (m, 3H), 8.05 (dd, 1H, J = 5.2 and 1.2 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 28.2, 34.6, 53.2, 115.3, 116.9 (d, J = 25.7 Hz), 117.0 (dd, J = 24.1 and 8.0 Hz), 117.7 (dd, J = 22.5 and 8.8 Hz), 118.0, 121.6 (dd, J = 15.4 and 10.4 Hz), 125.6, 140.8, 142.9, 152.8, 154.4 (dd, J = 249.0 and 2.4 Hz), 158.4 (dd, J = 247.4 and 2.8 Hz). ¹⁹F NMR (CDCl₃, 376 MHz) δ -124.0 (d, J = 15.5 Hz), -177.4 (d, J = 15.5 Hz); Anal. Calcd. For C₁₇H₁₇F₂N₃O: C, 64.34; H, 5.40; N, 13.24. Found: C, 64.20; H, 5.19; N, 13.13.



 N^3 -(2,2-Dimethylpropyl)- N^2 -(4-morpholin-4-ylphenyl)pyridine-2,3-diamine (11). According to the general procedure for the preparation of unsymmetrically substituted diamines, treatment of 450 mg (2.26 mmol) of **8** with 540 mg (3.00 mmol) of 4-morpholinoaniline gave 520 mg (67%) of **11** which was used in the next step without further purification. ¹H NMR (CDCl₃, 400 MHz) δ 0.97 (s, 9H), 2.83 (d, 2H, *J* = 5.2 Hz), 3.09 (m, 4H), 3.32 (br t, 1H, *J* = 5.6 Hz), 3.87 (m, 4H), 6.13 (br s, 1H), 6.81 (dd, 1H, *J* = 7.8 and 5.0 Hz), 6.90 (m, 2H), 6.93 (dd, 1H, *J* = 7.8 and 1.4 Hz), 7.15 (m, 2H), 7.72 (dd, 1H, *J* = 5.0 and 1.4 Hz);); ¹³C NMR (CDCl₃, 100 MHz,) δ 27.7, 31.7, 50.6, 56.1, 67.1, 117.2, 117.3, 118.3, 120.6, 134.5, 135.0, 136.8, 146.0, 146.8.




1-(2,2-Dimethylpropyl)-3-(4-morpholin-4-ylphenyl)-1,3-dihydro-2*H***-imidazo[4,5***b***]pyridin-2-one (12). According to the general procedure for the preparation of imidazo[4,5-***b***]pyridin-2-ones, treatment of 380 mg (1.11 mmol) of diamine 11** with 200 mg (0.674 mmol) of triphosgene gave 370 mg (90%) of **12** as a white solid: mp 172 °C; ¹H NMR (CDCl₃, 400 MHz) δ 1.09 (s, 9H), 3.22 (m, 4H), 3.73 (s, 2H), 3.90 (m, 4H), 7.03 (dd, 1H, J = 8.0 and 5.2 Hz), 7.07 (m, 2H), 7.27 (dd, 1H, J = 7.8 and 1.4 Hz), 7.59 (m, 2H), 8.05 (dd, 1H, J = 5.0 and 1.4 Hz); ¹³C (CDCl₃, 100 MHz) δ 28.3, 34.6, 49.4, 53.0, 66.8, 114.6, 116.2, 116.3, 117.2, 125.3, 126.9, 140.6, 143.6, 150.4, 153.8; Anal. Calcd. For C₂₁H₂₆N₄O₂: C, 68.83; H, 7.15; N, 15.29. Found: C, 68.43; H, 7.04; N, 15.05.




13

2-Chloro-*N***-(tetrahydrofuran-2-ylmethyl)pyridin-3-amine (13).** According to the general procedure for the preparation of 3-amino-2-chloropyridines, reaction of 5.00 g (20.9 mmol) of **4** with 2.01 g (19.9 mmol) of tetrahydrofurfuryl amine afforded 3.12 g (74%) of **13** as a yellow oil: ¹H NMR (CDCl₃, 400 MHz) δ 1.68 (m, 1H), 1.06 (m, 2H), 2.07 (m, 1H), 3.15 (m, 1H), 3.30 (m, 1H), 3.81 (m, 1H), 3.92 (m, 1H), 4.16 (m, 1H), 4.68 (br t, 1H, *J* = 6.0 Hz), 6.92 (dd, 1H, *J* = 8.0 and 1.6 Hz), 7.08 (dd, 1H, *J* = 8.0 and 4.4 Hz), 7.72 (dd, 1H, *J* = 4.8 and 1.6 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 25.9, 29.2, 47.4, 68.4, 77.3, 117.5, 123.3, 136.5, 137.4, 141.1. HRMS (EI) calcd for (M + H⁺) C₁₀H₁₃CINO: 213.0795. Found: 213.0795.




 N^2 -1,3-Benzodioxol-5-yl- N^3 -(tetrahydrofuran-2-ylmethyl)pyridin-2,3-diamine (14). According to the general procedure for the preparation of unsymmetrically substituted diamines, reaction of 500 mg (2.35 mmol) of 13 with 310 mg (2.30 mmol) of 3,4- (methylenedioxy)aniline gave 574 mg (78%) of 14 which was used in the next step without further purification: ¹H NMR (CDCl₃, 400 MHz) δ 1.67 (m, 1H), 1.95 (quint, 2H, J = 6.8 Hz), 2.06 (m, 1H), 3.05 (dd, 1H, J = 12.0 and 7.6 Hz), 3.19 (dd, 1H, J = 12.2 and 3.4 Hz), 3.68 (br s, 1H), 3.81 (m, 1H), 3.89 (m, 1H), 4.18 (m, 1H), 5.93 (s, 2H), 6.34 (br s, 1H), 6.66 (dd, 1H, J = 8.4 and 2.0 Hz), 6.74 (d, 1H, J = 8.0 Hz), 6.77 (dd, 1H, J = 7.6 and 5.2 Hz), 6.94 (dd, 1H, J = 7.6 and 1.6 Hz), 7.04 (d, 1H, J = 2.4 Hz), 7.77 (dd, 1H, J = 7.6 = 4.8 and 1.4 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 25.9, 29.2, 48.9, 68.2, 77.5, 101.0, 102.5, 108.2, 112.1, 116.5, 119.3, 133.0, 136.1, 137.8, 142.6, 146.8, 147.9.




3-(1,3-Benzodioxol-5-yl)-1-(tetrahydrofuran-2-yl-methyl)-1,3-dihydro-2H-

imidazo[4,5-*b***]pyridin-2-one (15).** According to the general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatment of 740 mg (2.36 mmol) of diamine **14** with 280 mg (0.943 mmol) of triphosgene gave 270 mg (65%) of **15** as an oil: ¹H NMR (CDCl₃, 400MHz) δ 1.67 (m, 1H), 1.81 (quint, 2H), 2.00 (m, 1H), 3.66 (q, 1H, *J* = 7.4 Hz), 3.76 (q, 1H, *J* = 6.8 Hz), 3.85 (dd, 1H, *J* = 14.9 and 3.8 Hz), 4.03 (m, 1H), 4.20 (m, 1H), 5.92 (s, 2H), 6.85 (d, 1H, *J* = 8.8 Hz), 6.96 (dd, 1H, *J* = 7.63 and 5.2 Hz), 7.06 (m, 2H), 7.38 (dd, 1H, *J* = 7.6 and 1.2 Hz), 7.95 (dd, 1H, *J* = 5.2 and 1.2 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 25.8, 28.8, 45.4, 68.2, 77.8, 101.7, 107.7, 108.3, 115.5, 117.8, 120.0, 124.5, 127.0, 140.8, 143.4, 147.1, 148.0, 153.1; HRMS (EI) calcd for (M + H⁺) for 340.1295. Found: 340.1297.




2-Chloro-*N***-(2,2-dimethoxyethyl)pyridin-3-amine (16).** According to the general procedure for 3-amino-2-chloropyridines, reaction of 5.00 g (20.9 mmol) of **4** with 2.08 g

(19.9 mmol) of aminoacetaldehyde dimethyl acetal afforded 3.18 g (74%) of **16** as a yellow oil: ¹H NMR (CDCl₃, 400 MHz) δ 3.29 (t, 2H, *J* = 5.6 Hz), 3.45 (s, 6H), 4.58 (br s, 1H), 4.59 (t, 1H, *J* = 5.4 Hz), 6.93 (dd, 1H, *J* = 7.6 and 1.4 Hz), 7.10 (dd, 1H, *J* = 8.0 and 4.8 Hz), 7.74 (dd, 1H, *J* = 4.8 and 1.6 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 45.0, 54.2, 102.5, 117.7, 123.4, 136.7, 137.4, 140.6; Anal. Calcd. for C₉H₁₃ClN₂O₂: C, 49.89; H, 6.05; N, 12.93. Found: C, 50.22; H, 5.80; N, 12.71.




4-({**3**-[(**2**,**2**-Dimethoxyethyl)amino]pyridin-2-yl}amino)benzonitrile (17). According to the general procedure for preparation of unsymmetrically substituted diamines, treatment of 600 mg (2.77mmol) of **16** with 340 mg (2.88 mmol) of 4-aminobenzonitrile gave 719 mg (87%) of **17** which was used in the next step without further purification: ¹H NMR (CDCl₃, 400MHz) δ 3.20 (t, 2H, *J* = 5.6 Hz), 3.40 (s, 6H), 3.72 (br t, 1H, *J* = 5.6 Hz), 4.56 (t, 1H, *J* = 5.2 Hz), 6.90 (dd, 1H, *J* = 8.0 and 4.8 Hz), 6.92 (br s, 1H), 7.00 (dd, 1H, *J* = 7.6 and 1.2 Hz), 7.30 (dt, 2H, *J* = 8.8 and 2.2 Hz), 7.45 (dt, 2H, *J* = 8.8 and 2.2 Hz), 7.81 (dd, 1H, *J* = 4.8 and 1.6 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 46.0, 54.2, 102.6, 102.8, 117.4, 119.1, 120.0, 120.4, 133.2, 134.3, 137.7, 143.9, 146.1.




4-[1-(2,2-Dimethoxyethyl)-2-oxo-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-

yl]benzonitrile (**18**). According to the general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatment of 830 mg (2.77 mmol) of **17** with 330 mg (1.11 mmol) of triphosgene gave 720 mg (80%) of **18** as an off-white solid. mp 113-114 °C, ¹H NMR (CDCl₃, 400 MHz) δ 3.46 (s, 6H), 4.06 (d, 2H, J = 4.8 Hz), 4.65 (t, 1H, J = 4.8 Hz), 7.14 (dd, 1H, J = 8.0 and 5.2 Hz), 7.46 (dd, 1H, J = 7.8 and 1.2 Hz), 7.81 (dt, 2H, J = 9.2 and 2.0 Hz), 8.09 (dd, 1H, J = 5.0 and 1.6 Hz), 8.12 (dt, 2H, J = 8.8 and 2.0 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 43.6, 55.3, 102.9, 110.4, 116.0, 118.5, 118.8, 124.6, 125.3, 133.0, 138.0, 141.0, 142.3, 152.2; Anal. Calcd. for C₁₇H₁₆N₄O₃: C, 62.95; H, 4.95; N, 17.27. Found: C, 62.84; H, 4.80; N 17.14.




2-Chloro-*N***-(2,5-difluorophenyl)pyridin-3-amine (19).** According to the general procedure for the preparation of 3-amino-2-chloropyridines, reaction of 700 mg (2.9 mmol) of **4** with 370 mg (2.87 mmol) of 2,5-difluoroaniline afforded 580 mg (84%) of **19** as a white solid: mp 109-110 °C; ¹H NMR (CDCl₃, 400 MHz) δ 6.22 (br s, 1H), 6.69 (m,

1H), 6.99 (m, 1H), 7.10 (m, 1H), 7.18 (m, 1H), 7.54 (dd, 1H, J = 8.0 and 1.2 Hz), 7.9 (dd, 1H, J = 4.8 and 1.8 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 106.3 (d, J = 27.3 Hz), 109.1 (dd, J = 24.1 and 7.2 Hz), 116.6 (dd, J = 22.1 and 10.0 Hz), 123.1, 123.3, 130.0 (dd, J = 12.8 and 11.2 Hz), 135.6, 140.4, 141.2, 150.3 (dd, J = 240.1 and 2.4 Hz), 158.9 (dd, J = 242.8 and 2.4 Hz); ¹⁹F NMR (CDCl₃, 376 MHz) δ -135.0 (d, J = 15.5 Hz), -117.0 (d, J = 15.5 Hz). Anal. Calcd. for C₁₁H₇ClF₂N₂: C, 54.90; H, 2.93; N, 11.64. Found: C, 54.81; H, 2.74; N, 11.47.




*N*³-(2,5-Difluorophenyl)-*N*²-(4-methoxyphenyl)pyridine-2,3-diamine (20). According to the general procedure for the preparation of unsymmetrically substituted diamines, treatment of 250 mg (1.04 mmol) of **19** with 130 mg (2.5 mmol) of *p*-anisidine provided 190 mg (56%) of **20** as a fluffy white solid: mp 116-117 °C; ¹H NMR (CDCl₃, 400 MHz) δ 3.79 (s, 3H), 5.47 (br s, 1H), 6.38 (m, 1H), 6.47 (m, 1H), 6.74 (dd, 1H, *J* = 7.6 and 4.8 Hz), 6.78 (br s, 1H), 6.87 (m, 2H), 7.03 (m, 1H), 7.39 (dd, 1H, *J* = 7.8 and 1.2 Hz), 7.43 (m, 2H), 8.12 (dd, 1H, *J* = 4.8 and 1.6 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 55.6, 102.5 (dd, *J* = 28.9 and 2.1 Hz), 105.3 (dd, *J* = 24.0 and 7.2 Hz), 114.3 114.6, 115.7 (dd, *J* = 20.9 and 10.4 Hz), 121.9, 122.3, 133.3, 133.5, 124.9 (dd, *J* = 11.4 and 12.8), 145.6, 148.3 (d, *J* = 235.0 Hz), 153.2, 155.6, 159.5 (d, *J* = 240.9 Hz); ¹⁹F NMR (CDCl₃,


376 MHz) δ -140.9 (d, J = 15.5 Hz), -117.3 (d, J = 17.2 Hz); Anal. Calcd for C₁₈H₁₅F₂N₃O: C, 66.05; H, 4.62; N, 12.84. Found: C, 65.82; H, 4.45; N 12.60.



1-(2,5-Difluorophenyl)-3-(4-methoxyphenyl)-1,3-dihydro-*2H***-imidazo**[**4,5-***b*]**pyridin-2-one (21).** According to the general procedure for the preparation of imidazo[**4**,5-*b*]**pyridin-2-ones, treatment of 160 mg (0.49 mmol) of 20** with 58.0 mg (0.195 mmol) of triphosgene gave 150 mg (88%) of **21** as a fluffy white solid: mp 172-173 °C; ¹H NMR (CDCl₃, 400 MHz) δ 3.88 (s, 3H), 7.08 (m, 3H), 7.19 (m, 2H), 7.31 (m, 1H), 7.38 (m, 1H), 7.64 (m, 2H), 8.15 (dd, 1H, *J* = 5.0 and 1.4 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 55.6, 114.7, 115.4, 116.3 (d, *J* = 25.7 Hz), 117.1 (dd, *J* = 23.7 and 7.6 Hz), 117.99 (dd, *J* = 22.9 and 9.2 Hz), 118.01, 123.4, 125.6, 127.6, 137.2, 142.1, 143.7, 151.2, 153.8, (dd, 249.0 and 3.2 Hz), 158.5 (dd, *J* = 248.0 and 2.4 Hz), 159.3; ¹⁹F NMR (CDCl₃, 376 MHz) δ -123.9 (d, *J* = 15.5), -116.4 (d, *J* = 15.5 Hz). Anal. Calcd. for C₁₉H₁₃F₂N₃O₂: C, 64.59; H, 3.71; N, 11.89. Found: C, 64.38; H, 3.39; N, 11.81.



Preparation of 2-Chloro-*N***-cyclohexylpyridin-3-amine (22).** According to the general procedure for the preparation of 3-amino-2-chloropyridines, reaction of 8.00 g (33.4 mmol) of **4** with 3.14 g (31.7 mmol) of cyclohexylamine gave 5.67 g (85%) of **22** as a colorless solid: mp 44-45 °C; ¹H NMR (CDCl₃, 400 MHz) δ 1.26 (m, 5H), 1.63 (m, 1H), 1.75 (m, 2H), 2.02 (m, 2H), 3.24 (m, 1H), 4.25 (br s, 1H), 6.86 (dd, 1H, *J* = 8.1 and 1.5 Hz), 7.04 (dd, 1H, *J* = 8.1 and 4.6 Hz), 7.64 (dd, 1H, *J* = 4.6 and 1.5 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 24.7, 25.7, 32.8, 51.1, 117.6, 123.3, 135.7, 136.9, 139.9; Anal. Calcd. For C₁₁H₁₅ClN₂: C, 62.70; H, 7.18; N, 13.30. Found: C, 63.00; H, 7.28; N, 13.14.




Preparationof N^3 -Cyclohexyl- N^2 -(4-{[4-(methylsulfonyl)piperazin-1-yl]methyl}phenyl)pyridine-2,3-diamine (23).A solution of 1.00 g (4.63 mmol) of 4-nitrobenzyl bromide in 5 mL of isopropyl acetate was added dropwise over a period of 20min to a stirred solution of 4 g (46.4 mmol) of piperazine in 8 mL of 95% EtOH.Theresulting suspension was allowed to stir at rt for 30 min, filtered over a pad of celite andconcentrated under reduced pressure.The residue was dissolved in 30 mL of isopropylacetate and washed with 25 mL of water.The isopropyl acetate layer was separated andconcentrated to a final volume of 20 mL.To the solution was added 610 mg (6.01 mmol)

of NEt₃ followed by 560 mg (4.86 mmol) of methanesulfonyl chloride. After stirring for 30 min the reaction mixture was filtered over a pad of celite and concentrated to a final volume of 20 mL. To the resulting mixture was added 20 mL of heptane and the slurry of the product was stirred for 20 min and filtered affording 900 mg (65%) of 1-methanesulfonyl-4-(4-nitrobenzyl)-piperazine as a colorless solid: mp 116-117 °C; ¹H NMR (CDCl₃, 400 MHz) δ 2.58 (m, 4H), 2.80 (s, 3H), 3.27 (m, 4H), 3.65 (s, 2H), 7.51 (d, 2H, *J* = 8.8 Hz), 8.18 (d, 2H, *J* = 8.8 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 34.5, 46.0, 52.6, 61.8, 123.8, 129.6, 145.7, 147.5; Anal. Calcd. For C₁₂H₁₇N₃O₄S: C, 48.15; H, 5.72; N, 14.04. Found: C, 48.16; H, 5.52; N, 13.91.


To a solution of 25.0 g (83.5 mmol) of the above nitrocompound in 1.50 L of EtOAc was added 5.00 g of 5% Pd/C. The resulting mixture stirred at rt under an atmosphere of hydrogen (15 psi) for 4 h. The reaction mixture was filtered over a pad of celite and concentrated to a solid under reduced pressure to give 19.0 g (84%) of 4-(4-methanesulfonyl-piperazin-1-ylmethyl)aniline as a colorless solid: mp 161-162 °C; ¹H NMR (CDCl₃, 400 MHz) δ 2.52 (m, 4H), 2.76 (s, 3H), 3.22 (m, 4H), 3.42 (s, 2H), 3.67 (br s, 2H), 6.63 (d, 2H, *J* = 8.4 Hz), 7.06 (d, 2H, *J* = 8.4 Hz); ¹³C NMR (CDCl₃, 100 MHz)) δ 34.1, 46.0, 52.1, 62.3, 115.0, 127.2, 130.4, 145.8; Anal. Calcd. For C₁₂H₁₉N₃O₂S: C, 53.51; H, 7.11; N, 15.60. Found: C, 53.71; H, 7.09; N, 15.48.

According to the general procedure for the preparation of unsymmetrically substituted diamines, treatment of 250 mg (1.19 mmol) of **22** with 380 mg (1.41 mmol) of the above aniline afforded 504 mg (95%) of **23** as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 1.21 (m, 3H), 1.31 (m, 2H), 1.65 (m, 1H), 1.73 (m, 2H), 1.99 (m, 2H), 2.54 (m, 4H), 2.76 (s, 3H), 3.22 (m, 6H), 3.47 (s, 2H), 6.24 (br s, 1H), 6.82 (m, 1H), 6.95 (dd, 1H, *J* = 7.7 and 1.3


Hz), 7.19 (s, 4H), 7.75 (dd, 1H, *J* = 4.9 and 1.3 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 24.8, 25.9, 33.2, 34.1, 45.9, 52.0, 51.1, 62.2, 117.6, 118.1, 119.8, 129.9, 133.0, 136.9, 141.1, 145.5.




Preparationof1-Cyclohexyl-3-(4-{[4-(methylsulfonyl)piperazin-1-yl]methyl}phenyl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridin-2-one(24). According tothe general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatment of410 mg (0.924 mmol) of 23 with 110 mg (0.370 mmol) of triphosgene gave 410 mg(94%) of 24 as a yellow foam: ¹H NMR (CDCl₃, 400 MHz) δ 1.29 (m, 1H), 1.46 (m,2H), 1.76 (m, 1H), 1.96 (m, 4H), 2.10 (m, 2H), 2.58 (m, 4H), 2.77 (s, 3H), 3.24 (m, 4H),3.58 (s, 2H), 4.37 (m, 1H), 7.03 (dd, 1H, *J* = 8.0 and 5.2 Hz), 7.45 (m, 3H), 7.65 (d, 2H, *J*= 8.4 Hz), 8.02 (dd, 1H, *J* = 5.2 and 1.3 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 25.4, 25.9,30.3, 34.3, 46.0, 52.4, 53.2, 62.2, 115.4, 117.4, 123.0, 126.0, 129.7, 132.7, 136.9, 140.3,143.3, 152.3; Anal. Calcd. For C₂₄H₃₁N₅O₃S: C, 61.38; H, 6.65; N, 14.91. Found: C,61.57; H, 6.87; N, 14.79.



Preaparion of 2-Chloro-*N*-[3-(4-methylpiperazin-1-yl)propyl]pyridin-3-amine (25). According to the general procedure for the preparation of 3-amino-2-chloropyridines, reaction of 8.01 g (33.45 mmol) of **4** with 5.00 g (31.79 mmol) of 1-(3-aminopropyl)-4-methylpiperazine gave 7.09 g (83%) of **25** as an oil which was used in the next step without further purification: ¹H NMR (CDCl₃, 400 MHz) δ 1.83 (m, 2H), 2.28 (s, 3H), 2.49 (m, 10H), 3.18 (m, 2H), 5.68 (br s, 1H), 6.82 (m, 1H), 7.04 (m, 1H), 7.65 (m, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 24.8, 43.4, 46.1, 53.5, 54.9, 57.5, 116.9, 123.3, 135.7, 137.1, 141.4.




Preparation of N^3 -[3-(4-Methylpiperazin-1-yl)propyl]- N^2 -phenylpyridine-2,3diamine (26). According to the general procedure for the preparation of unsymmetrically substituted diamines, treatment of 1.40 g (5.21 mmol) of 25 with 613 mg (6.58 mmol) of aniline afforded 1.34 g (79%) of 26 as a clear oil: ¹H NMR (CDCl₃, 400 MHz) δ 185 (m, 2H), 2.11 (s, 3H), 2.50 (m, 10H), 3.18 (t, 2H, J = 6.0 Hz), 5.09 (br s, 1H), 6.03 (br s, 1H), 6.81 (m, 1H), 6.87 (m, 1H), 6.93 (m, 1H), 7.27 (m, 4H), 7.73 (m, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 25.2, 44.5, 45.8, 53.5, 55.1, 58.1, 117.1, 117.4, 118.9, 121.4, 128.9, 134.5, 136.2, 141.5, 145.2.




Preparation of 1-[3-(4-methylpiperazin-1-yl)propyl]-3-phenyl-1,3-dihydro-2*H*imidazo[4,5-*b*]pyridin-2-one (27)². According to the general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatment of 1.00 g (3.07 mmol) of 26 with 364 mg (1.23 mmol) of triphosgene gave 993 mg (92%) of 27² as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 1.98 (m, 2H), 2.31 (s, 3H), 2.44 (m, 10H), 4.01 (t, 2H, *J* = 6.8 Hz), 7.04 (dd, 1H, *J* = 7.8 and 5.2 Hz), 7.23 (m, 1H), 7.41 (m, 1H), 7.51 (t, 2H, *J* = 8.0 Hz), 7.73 (m, 2H), 8.04 (dd, 1H, *J* = 5.2 and 1.2 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 25.3, 39.1, 45.7, 52.6, 54.9, 55.0, 113.9, 117.6, 124.1, 125.7, 127.5, 129.1, 133.4, 140.6, 143.2, 152.6; Anal. Calcd. For C₂₀H₂₅N₅O: C, 68.35; H, 7.17; N, 19.93. Found: C, 68.14; H, 6.98; N, 19.92.

General Procedure for Symmetrically Substituted Diamines: To 3.00 g (12.5 mmol) of 2-chloro-3-iodopyridine (4) in 31 mL of toluene was added sequentually 10 mg (0.376 mmol) of Pd(OAc)₂, 84 mg (0.376 mmol) of *rac*-BINAP, 1.37 g (62.5 mmol) of Cs₂CO₃, 31.3 mmol of the appropriate aniline, and 75.0 mg (0.752 mmol) of triethylamine. The resulting slurry was degassed (2X) by vacuum/N₂ backfills. The mixture was heated to


reflux and monitored by TLC (25% EtOAc/hexane) for the dissappearance of starting materials. After 18 h the reaction mixture was cooled to rt and 30 mL of H_2O was added. The layers were separated and the toluene layer was concentrated under reduced pressure. The residue could be used crude without further purification in the next step or purified by silica gel chromatography.



Preparation of *N*,*N***'-Diphenylpyridine-2,3-diamine (28).** According to the general procedure for the preparation of symmetrically substituted diamines, reaction of 4.00 g (16.7 mmol) of **4** with 3.85 g (41.4 mmol) of aniline afforded 3.63 g (83%) of **28** as a colorless solid: mp 127-128 °C; ¹H NMR (CDCl₃, 400 MHz) δ 5.18 (br s, 1H), 6.81 (m, 3H), 6.94 (m, 2H), 7.01 (t, 1H, *J* = 7.4 Hz), 7.32 (m, 4H), 7.42 (m, 1H), 7.56 (m, 2H), 8.13 (dd, 1H, *J* = 4.9 and 1.5 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 115.2, 116.0, 119.2, 120.5, 121.9, 125.2, 128.9, 129.4, 131.7, 140.6, 143.9, 144.8, 151.8; Anal. Calcd. For $C_{17}H_{15}N_3$: C, 78.13; H, 5.79; H, 16.08. Found: C, 78.35; H, 5.46; N, 16.01.




Preparation of 1,3-Diphenyl-1,3-dihydro-*2H***-imidazo**[4,5-*b*]**pyridin-2-one** (29). According to the general procedure for the preparation of imidazo[4,5-*b*]**pyridin-2-ones**, treatment of 1.50 g (5.74 mmol) of **28** with 681 mg (2.30 mmol) of triphosgene yielded 1.60 g (97%) of **29** as colorless solid: mp 119-120 °C; ¹H NMR (CDCl₃, 400 MHz) δ 7.07 (dd, 1H, *J* = 7.8 and 5.2 Hz), 7.38 (dd, 1H, *J* = 7.8 and 1.5 Hz), 7.45 (m, 2H), 7.61 (m, 6H), 7.80 (m, 2H), 8.14 (dd, 1H, *J* = 5.2 and 1.5 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 115.0, 118.0, 123.9, 125.8, 126.2, 127.8, 128.1, 129.3, 129.8, 133.3, 133.9, 141.7, 143.4, 151.8; Anal. Calcd. For C₁₈H₁₃N₃O: C, 75.25; H, 4.56; N, 14.63. Found: C, 75.17; H, 4.36; N, 14.50.




N, *N*-Bis(2,5-difluorophenyl)pyridine,2,3-diamine (30). According to the general procedure for the preparation of symmetrically substituted diamines, reaction of 700 mg (2.92 mmol) of **4** with 940 mg (7.30 mmol) of 2,5-difluoroaniline gave 867 mg (89%) of

30 which was used in the next step without further purification: ¹H NMR (CDCl₃, 400 MHz) δ 5.42 (br s, 1H), 6.34 (m, 1H), 6.50 (m, 1H), 6.60 (m, 1H), 6.90 (dd, 1H, *J* = 7.6 and 4.8 Hz), 7.00 (m, 1H), 7.06 (m, 1H), 7.37 (br s, 1H), 7.50 (dd, 1H, *J* = 7.6 and 1.6 Hz), 8.24 (dd, 1H, *J* = 5.2 and 1.6 Hz), 8.50 (m, 1H); ¹³C NMR (CDCl₃, 100 MHz,) δ 102.6 (dd, *J* = 28.7 and 2.4 Hz), 105.9 (dd, *J* = 24.1 and 7.2 Hz), 106.9 (dd, *J* = 24.9 and 7.2 Hz), 107.0 (d, *J* = 30.5 Hz), 114.7 (dd, *J* = 21.7 and 9.6 Hz), 115.9 (dd, *J* = 20.9 and 10.4 Hz), 116.2, 123.2, 129.8 (dd, *J* = 12.0 and 11.2 Hz), 133.9, 134.5 (dd, *J* = 13.7 and 11.2 Hz), 145.4, 148.2 (dd, *J* = 237.7 and 3.2 Hz), 148.3 (dd, *J* = 236.9 and 3.2 Hz), 151.5, 159.3 (dd, *J* = 239.1 and 2.0 Hz), 159.5 (dd, *J* = 24.9 and 1.6 Hz).




1,3-Bis(2,5-difluorophenyl)-1,3-dihydro-*2H***-imidazo[4,5-***b***]pyridin-2-one** (33). According to the general procedure for the preparation of imidazo[4,5-*b*]**pyridin-2-ones**, treatment of 970 mg (2.91 mmol) of **30** with 340 mg (1.14 mmol) of triphosgene gave 850 mg (81%) of **33** as an off-white solid: mp 130-132 °C; ¹H NMR (CDCl₃, 400 MHz) δ 7.13 (dd, 1H, *J* = 8.0 and 5.2 Hz), 7.21 (m, 3H), 7.34 (m, 4H), 8.15 (dd, 1H, *J* = 5.2 and 1.2 Hz); ¹³C NMR (CDCl₃, 100 MHz,) δ 115.9 (d, *J* = 3.2 Hz), 116.2 (d, *J* = 25.7 Hz), 116.9 (d, *J* = 25.7 Hz), 117.4 (dd, *J* = 24.1 and 8.8 Hz), 117.5 (dd, *J* = 24.1, 8.8 Hz), 117.9 (dd, *J* = 22.5 and 9.6 Hz), 118.1 (dd, *J* = 22.5 and 8.8 Hz), 118.6, 120.9 (dd, *J* = 14.5 and 11.4 Hz), 123.7, 142.3, 142.9, 150.4, 153.8


(dd, J = 249.8 and 3.2 Hz), 154.4 (dd, J = 249.8 and 3.2 Hz), 158.4 (dd, J = 249.8 and 3.2 Hz), 158.6 (dd, J = 249.0 and 3.2 Hz); ¹⁹F NMR (CDCl₃, 376 MHz) δ -123.9 (d, J = 15.5 Hz), -123.8 (d, J = 17.2 Hz), -117.1 (d, J = 17.2 Hz), -116.2 (d, J = 15.5 Hz); Anal. Caldc. For C₁₈H₉F₄N₃O·1/4 H₂O: C, 59.43; H, 2.23; N, 11.50. Found: C, 59.66; H, 2.25; N, 11.55.



Preparation of *N*,*N*'-Bis[3-(trifluoromethyl)phenyl]pyridine-2,3-diamine (31). According to the general procedure for the preparation of symmetrically substituted diamines, reaction of 4.07 g (17.0 mmol) of **4** with 6.85 g (42.5 mmol) of 3- (trifluoromethyl)aniline afforded 5.98 g (89%) of **31** as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 5.51 (br s, 1H), 6.86 (m, 2H), 7.03 (d, 2H, J = 10.6 Hz), 7.17 (d, 1H, J = 7.7 Hz), 7.23 (d, 1H, J = 7.7 Hz), 7.35 (q, 2H, J = 8.1 Hz), 7.43 (d, 1H, J = 7.7 Hz), 7.69 (d, 1H, J = 8.1 Hz), 7.89 (s, 1H), 8.17 (m, 1H); ¹³C NMR (CDCl₃, 100 MHz,) δ 112.3 (d, J = 4.0 Hz), 115.6 (d, J = 4.0 Hz), 116.3, 117.1 (d, J = 4.0 Hz), 118.4 (d, J = 4.0 Hz), 122.1, 124.1 (q, J = 271.0 Hz), 124.2, 124.3 (q, J = 271.0 Hz), 129.4, 130.2, 131.4 (q, J = 31.0 Hz), 132.0 (q, J = 31.0 Hz), 133.0, 140.9, 144.8, 145.4, 151.6; ¹⁹F NMR (CDCl₃, 376 MHz) δ -63.2, -63.3.




Preparation of 1,3-Bis[3-trifluoromethyl)phenyl]-1,3-dihydro-2*H*-imadazo[4,5*b*]pyridin-2-one (34). According to the general procedure for the preparation of imidazo[4,5-*b*]pyridin-2-ones, treatement of 1.50 g (3.79 mmol) of **31** with 450 mg (1.52 mmol) of triphosgene gave 1.53 g (95%) of **34** as a colorless solid: mp 181-182 °C; ¹H NMR (CDCl₃, 400 MHz) δ 7.16 (dd, 1H, *J* = 7.8 and 5.2 Hz), 7.42 (dd, 1H, *J* = 7.8 and 1.4 Hz), 7.73 (m, 4H), 7.84 (m, 1H), 7.91 (s, 1H), 8.07 (m, 1H), 8.20 (m, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ 115.3, 118.7, 122.5 (d, *J* = 4.0 Hz), 122.8 (d, *J* = 4.0 Hz), 123.3, 123.5 (q, *J* = 271.0 Hz), 123.7 (q, *J* = 271.0 Hz), 124.4 (d, *J* = 4.0 Hz), 125.0 (d, *J* = 4.0 Hz), 128.9, 129.0, 130.5, 131.7 (q, *J* = 33.0 Hz), 132.5 (q, *J* = 33.0 Hz), 133.8, 134.3, 142.2, 142.9, 151.2; ¹⁹F NMR (CDCl₃, 376 MHz) δ -63.14, -63.26; Anal. Calcd. For C₂₀H₁₁F₆N₃O: C, 56.75; H, 2.62; N, 9.93. Found: C, 56.47; H, 2.41; N, 9.82.




Preparation of *N*,*N*-**Di-1-naphthylpyridine-2,3-diamine (32).** According to the general procedure for the preparation of symmetrically substituted diamines, reaction of

2.00 g (8.35 mmol) of **4** with 2.99 g (20.9 mmol) of 1-aminonaphthalene gave 2.41 g (80%) of **32** which was used in the next step without further purification: ¹H NMR (CDCl₃, 400 MHz) δ 5.98 (br s, 1H), 6.81 (dd, 1H, *J* = 7.6 and 4.8 Hz), 6.90 (d, 1H, *J* = 7.2 Hz), 7.22 – 7.60 (m, 10 H), 7.64 (d, 1H, *J* = 8.0 Hz), 7.83 (d, 1H, *J* = 8.0 Hz), 7.93 (d, 1H, *J* = 8.0 Hz), 7.97 (d, 1H, *J* = 7.6 Hz), 8.03 (dd, 1H, *J* = 7.6 and 1.2 Hz), 8.12 (dd, 1H, *J* = 4.8 and 1.6 Hz) ¹³C NMR (CDCl₃, 100 MHz) δ 112.8, 116.0, 116.8, 121.1, 122.2, 123.2, 125.6, 125.7, 125.8, 126.0, 126.2, 126.3, 126.95, 127.04, 128.3, 128.6, 128.8, 129.1, 130.5, 134.4, 134.7, 135.9, 139.4, 143.1, 150.7.




1,3-Di-(1-naphthyl-1,3-dihydro-2*H***-imidazo[4,5-***b***]pyridin-2-one** (**35**). According to the general procedure for the preparation of imidazo[4,5-*b*]**pyridin-2-ones**, treatment of 1.92 g (5.31 mmol) of **32** with 630 mg (2.1 mmol) of triphosgene gave 1.73 g (84%) of **35** as a light purple solid. mp: 231-232 °C; ¹H NMR (CDCl₃, 400 MHz) δ 7.00 (m, 2H), 7.52-7.82 (m, 10H), 8.03 (m, 5H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 115.0 and 115.1 (due to rotomers), 118.2 and 118.1 (due to rotomers), 122.5, 122.91 and 122.93 (due to rotomers), 123.2, 125.4 and 125.5 (due to rotomers), 125.74 and 125.76 (due to rotomers), 125.97 and 126.01 (due to rotomers), 126.55 and 126.59 (due to rotomers), 127.2 and 127.25 (due to rotomers), 127.33, 127.55 and 127.60 (due to rotomers), 127.88, 128.3 and 128.4 (due to rotomers), 128.5 and 128.6 (due to rotomers), 129.44 and 129.46 (due


to rotomers), 129.65 and 129.70 (due to rotomers), 129.74 and 129.77 (due to rotomers), 130.27 and 130.28 (due to rotomers), 133.99 and 134.00 (due to rotomers), 134.2, 140.8 and 140.9 (due to rotomers), 144.3 and 144.4 (due to rotomers), 152.1 and 152.2 (due to rotomers); Anal. Calcd for $C_{26}H_{17}N_3O$: C, 80.60; H, 4.42; N, 10.85. Found: C, 80.27; H, 4.28; N, 10.77.



Preparation of 1,4-Diphenyl-1,4-dihydropyrido[2,3-*b*]**pyrazine-2,3-diamine (36).** To a stirred solution of 350 mg (1.34 mmol) of **28** in 8 mL of THF was added 312 mg (3.09 mmol) of triethylamine followed by 189 mg (1.49 mmol) of oxalyl chloride. After stirring for 15 min at rt, the reaction was diluted with EtOAc and then quenched with 8 mL of sat. aqueous NaHCO₃. The organic layer was dried over MgSO₄ and the solvent removed under reduced pressure. The residual solid was recrystallized from EtOAc/hexane to give 400 mg (95%) of **36** as a tan solid: mp 300 °C (decomp); ¹H NMR (CDCl₃, 400 MHz) δ 6.76 (dd, 1H, *J* = 8.1 and 1.3 Hz), 7.05 (dd, 1H, *J* = 8.1 and 4.6 Hz), 7.35 (d, 2H, *J* = 7.4 Hz), 7.45 (m, 3H), 7.55 (m, 3H), 7.66 (m, 2H), 7.95 (dd, 1H, *J* = 4.6 and 1.3 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 119.6, 123.4, 125.9, 128.8, 128.9, 129.3, 129.7, 129.9, 130.9, 136.3, 136.9, 140.8, 142.0, 154.5, 155.7; Anal. Calcd. For C₁₉H₁₃N₃O₂: C, 72.37; H, 4.16; N, 13.33. Found: C, 72.61; H, 4.08; N, 13.13.



Preparation of 1,4-Bis[3-(Trifluoromethyl)phenyl]-1,4-dihydropyrido[2,3*b*]pyrazine-2,3-dione (37). To a stirred solution of 1.15 mg (2.91 mmol) of 31 in 25 mL of THF was added 675 mg (6.67 mmol) of triethylamine followed by 407 mg (3.21 mmol) of oxalyl chloride. After stirring for 15 min at rt, the reaction was diluted with EtOAc and then quenched with 25 mL of sat. aqueous NaHCO₃. The organic layer was dried over MgSO₄ and the solvent removed under reduced pressure. The residual solid was recrystallized from EtOAc/hexane to give 1.27 g (97%) of 37 as a yellow solid: mp 319-320 °C; ¹H NMR (DMSO- d_6 , 400 MHz) δ 6.87 (dd, 1H, J = 8.2 and 1.3 Hz), 7.12 (dd, 1H, J = 8.2 and 4.7 Hz), 7.71 (m, 1H), 7.76 (m, 2H), 7.86 (m, 3H), 7.92 (m, 1H), 8.01 (m, 2H); ¹³C NMR (DMSO- d_6 , 100 MHz) δ 119.9, 123.6, 124.1 (q, J = 272.0 Hz), 124.3 (q, J = 272.0 Hz), 125.8, 125.9, 126.1, 126.9, 130.6 (q, J = 30.0 Hz), 131.2, 131.8 (q, J = 30.0 Hz), 133.5, 133.8, 136.9, 137.5, 140.6, 142.2, 154.5, 155.4; ¹⁹F NMR (DMSO-*d*₆, 376 MHz) -61.6, -61.8; Anal. Calcd. For C₂₁H₁₁F₆N₃O₂: C, 55.89; H, 2.46; N, 9.31. Found: C, 55.64; N, 2.24; N, 9.26.



Preparation of 1,3-Diphenyl-1,3-dihydro[1,2,5]thiadiazolo[3,4-*b*]pyridine-2-oxide (38). To a stirred solution of 371 mg (1.42 mmol) of 28 in 8 mL of THF was added 334 mg (3.30 mmol) of triethylamine followed by 179 mg (1.51 mmol) of thionyl chloride. After stirring at rt for 15 min the reaction was diluted with EtOAc and then quenched with 10 mL of sat. aqueous NaHCO₃. The organic layer was dried over MgSO₄ and the solvent removed under reduced pressure. The residual was purified by silica gel chromatography to give 388 mg (89%) of **38** as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 6.91 (dd, 1H, *J* = 7.8 and 5.1 Hz), 7.13 (dd, 1H, *J* = 7.8 and 1.3 Hz), 7.45 (m, 2H), 7.56 (m, 6H), 7.69 (m, 2H), 7.98 (dd, 1H, *J* = 5.1 and 1.3 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ 116.6, 116.7, 126.8, 126.9, 127.6, 128.4, 128.6, 129.9, 130.3, 134.5, 135.7, 140.5, 146.8; Anal. Calcd. For C₁₇H₁₃N₃OS: C, 66.43; H, 4.26; N, 13.67. Found: C, 66.40; H, 4.12; N, 13.49.

References

- 1. Sakamoto, T.; Kondo, Y.; Yamanaka, H. Chem. Pharm. Bull. 1985, 33, 4764.
- 2. Robinson, M. M.; Finch, N. U. S. Patent 3719683 (1973).

